ONCOblot® RESEARCH

CURRENT MEDICAL RESEARCH FROM ONCOblot® LABS

Presented by Humaira Khan, MBBS, MCPS, MHSc, Physician, Epidemiologist and Medicor C.E.O. and Akbar Khan, MD, Medicor Medical Director

The ONCOblot® blood test has been approved for human use since 2013 based on favourable human research. Internal research and published research is presented here. Researchers have used stored human blood samples from research subjects (“banked” frozen serum) to gather vital data on the accuracy of the ONCOblot® blood test. This is an exciting way to collect long-term data, without waiting years to complete the research! Human studies are ongoing, and new findings will be posted as soon as they become available.

Akbar Khan, MD

Medicor Director, Medicor Cancer Centres

Cancer Prevention Trial of a Synergistic Mixture of Green Tea Concentrate Plus Capsicum in a Random Population of Subjects Ages 40-84

“The study design was that of a non-randomized, open label and IRB-approved Phase II trial…One hundred ten (110) subjects were tested for cancer presence using the ONCOblot® [test]”

“Of the 110 subjects, both male and female, ages 40 to 84, with no evidence of clinical symptoms of cancer, 40% were positive for ENOX2 presence [indicating cancer presence]…non-small cell lung (20%), breast (16%), colorectal (9%), blood cell, ovarian, prostate and cervical all at 7% each.”

“After completion of 3 to 17 months of Capsol-T® use [green tea concentrate+ capsicum], 94% of subjects subsequently tested negative for ENOX2…”

“One patient, whose ONCOblot® test showed an ENOx2 protein indicative of non-small cell lung cancer, elected not to take the Capsol-T®, withdrew from the study and was clinically diagnosed with non-small cell lung cancer 36 months later.”

“Another patient whose original ONCOblot® test indicated leukemia/lymphoma withdrew from the study, elected not to take the Capsol-T®, and was clinically diagnosed with lymphoma 10 months later.”

ENOX2‑Based Early Detection (ONCOblot) of Asbestos‑Induced Malignant Mesothelioma 4–10 Years in Advance of Clinical Symptoms

“Sera from 17 individuals with confirmed malignant mesothelioma were studied.”

“Sequential serum samples [had been] collected from [these] asbestos-exposed individuals prior to the development of frank mesothelioma.

“The identification of specific ENOX2 isoforms in sera can be indicative of the presence of cancer and also indicative of the cancer site.”

“…mesothelioma-specific ENOX2 protein transcript variants were detected in the serum of asbestos-exposed individuals 4–10 years prior to clinical diagnosis of malignant mesothelioma (average 6.2 years).”

“For seven mesothelioma patients, annual serum samples were available before clinical diagnosis. For all seven, both ENOX2 protein isoforms were detected in pre-diagnostic serum samples available at least 4 years before diagnosis. For one subject, ENOX2 was detected 10 years prior to diagnosis.”

“To our knowledge, this is the earliest prediagnostic indicator of cancer thus far reported.”

ONCOblot® Accuracy 800 Samples - JAN 2013

“To test for accuracy, The ONCOblot® Test was performed on serum samples from over 800 different patients all with clinically diagnosed cancers. The type of cancer was blinded.”

“The ONCOblot® Test revealed the presence of ENOX2 in 99.3% of the samples from patients with confirmed cancers. Of those testing positive for ENOX2, the organ site of the cancer was determined correctly in 96% of the cases.”

ONCOblot® Consistently Detects Stage 0 and Stage I Cancers

“Sera from twenty-five stage 0 cancer patients and twenty-five stage I cancer patients confirmed by biopsy were analyzed…”

“For all 25 patients in each category, early cancers were detected by ONCOblot® and correctly identified as to tissue of origin.”

“With breast cancer, ductal carcinoma in situ (DCIS), is stage 0 and has not spread outside a breast duct or into the surrounding breast tissue.”

Incidence of ONCOblot® Detection of ENOX2 in Young Adults

“Sera of 50 male and 50 female volunteers, without clinical evidence of cancer, between 20 and 39 years of age were analyzed…”

“In the age group 20-29 years, none of the 25 females and only one (colorectal) of the 25 males exhibited ENOX2 proteins indicative of cancer presence.”

“…in the age group 30 to 39 years, one (blood cell) of the 25 females and one (prostate) of the 25 males exhibited ENOX2 proteins.”

“The difference between the present findings of a 3% incidence of ENOX2 proteins within 100 subjects from this age range and the predicted incidence of newly diagnosed cancers within this population [2%] is consistent with the previously estimated false positive rate of <1% for the ONCOblot®…”

ONCOblot® Accuracy 1500 Samples - APR 2015

“A false positive is the detection of an in-range ENOX2 transcript variant from a cancer-free individual that fails to appear upon subsequent analyses of the same serum sample. For the most recent 1500 ONCOblots® carried out according to current protocols, only one ONCOblot® result has been confirmed as a false positive (0.06%).”

“A false negative is the absence of an in range ENOX2 transcript variant from an individual with clinical symptoms arising from a clinically diagnosed (pathology) cancer, present at the time of testing and at an ENOX2 concentration above the limit of detection of the assay. For the most recent 1500 ONCOblots® carried out according to current protocols, only ten ONCOblot® results have been confirmed or suspected false negatives (0.6%).”

Estimation of Lower Limit of Detection of ENOX2 in Serum

“…the lower limit of detection of ENOX2 for the ONCOblot® test is <200 femtomoles per assay or a concentration of 1.3 nM of an ENOX2 protein within human serum.”

“This steady-state concentration of ENOX2 within an average adult is estimated to be produced by approximately 2 million cancer cells, which is equivalent to a solid tumor 1.2 mm in diameter.”

“By comparison…7 mm diameter breast cancers were detected approximately 50% of the time by mammography.”

Primary Tumors and Distant Metastases Produce Identical ENOX2 Protein Transcript Variants that Aid in the Identification of Cancers of Unknown Primary

“Although metastatic tumors develop at sites distant from the primary tumor, these metastatic tumors retain the phenotype and cell surface markers of the primary tumor, as the metastatic tumor cells are initially genetically identical to the cells of the primary tumor”

“Consistently, both metastatic tumors and the primary cancers from which they are derived produce identical ENOX2 protein transcript variants, which are then shed into blood serum. Therefore, detection of ENOX2 protein transcript variants shed by either a primary cancer or its distant metastases will yield similar ONCOblot® test results.”

As you can see, extensive human research has been conducted on the ONCOblot® test. Despite the relatively small patient numbers, the data is consistent, so physician acceptance, and use of the test is increasing rapidly. We recommend that you consult with a health professional such as a naturopathic doctor who can advise if and when this test is appropriate for you.

Humaira Khan, MBBS, MCPS, MHSc

Epidemiologist and Medicor CEO, Medicor Cancer Centres

FIND A DOCTOR TO OBTAIN THE ONCOblot® TEST